Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Jan 03, 2024 8:05am EST

Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 08, 2023 8:05am EST

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

Nov 07, 2023 4:01pm EST

Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 06, 2023 8:05am EST

Rigel to Present at the Jefferies London Healthcare Conference

Nov 02, 2023 9:27am EDT

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

Oct 31, 2023 8:05am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update

Oct 11, 2023 8:05am EDT

Rigel Announces Presentation at the Upcoming IDWeek 2023

Sep 20, 2023 8:05am EDT

Rigel to Present at the 2023 Cantor Global Healthcare Conference

Aug 30, 2023 8:05am EDT

Rigel to Participate in Upcoming September Investor Conferences

Aug 01, 2023 4:01pm EDT

Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …42
  • Next
RSS
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin